4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
Avidity Science(优势品牌)
主营:主营:酶,缓冲剂,酰,生物素克隆和表达系统,AviTag,蛋白质的纯化和鉴定
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > Other_reagents > 亲和性/BIS-300-BIS-300阳性和阴性对照蛋白试剂盒/1/BIS-300
商品详细亲和性/BIS-300-BIS-300阳性和阴性对照蛋白试剂盒/1/BIS-300
亲和性/BIS-300-BIS-300阳性和阴性对照蛋白试剂盒/1/BIS-300
亲和性/BIS-300-BIS-300阳性和阴性对照蛋白试剂盒/1/BIS-300
商品编号: BIS-300
品牌: Avidity Science
市场价: ¥3000.00
美元价: 2250.00
产地: 美国(厂家直采)
公司:
产品分类: 其他试剂
公司分类: Other_reagents
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍

Product Information

Kit supplied with the following:

  • One (1) vial containing 50μL of fully biotinylated MBP-AviTagTM fusion protein at 1mg/mL (50μg).
  • One (1) vial containing 100μL of unbiotinylated MBP-AviTagTM fusion protein at 1mg/mL (100μg).
  • By comparing a known amount of a 100% biotinylated AviTagTM fusion protein as a standard against a known amount of BirA-reacted protein-of-interest in an ELISA-type, multi-well dilution format (called BRTA for Biotinylation Reaction Titration Assay) it is possible to assess the extent of biotinylation achieved in your own BirA biotinylation reactions in a highly accurate and reproducible manner.

    In addition, a mass shift between biotinylated and unbiotinylated fusion proteins visible on both SDS-PAGE and Western blot can be used to subjectively determine the amount of biotinylation that has occurred in a reaction by the observation of differences in band density in a mixed population of biotinylated vs. nonbiotinylated substrate.

    The BIS-300 Kit contains the fully biotinylated standard used for the BRTA protocol and an unbiotinylated AviTag"d protein to react in a parallel to your BirA/protein biotinylation reaction as a positive control. A link to the BRTA protocol can be found here.

    品牌介绍
    亲和生物科学公司是一家私营生物技术公司,是一家开创抗体寡核苷酸结合(AOC)的公司。™)AOCs结合了单克隆抗体的组织选择性和基于寡核苷酸的治疗方法的精确性,以克服寡核苷酸传递的障碍和疾病的目标遗传驱动因素。它们的AOC平台,演示了疾病相关RNA在细胞类型和组织中的调节,包括肌肉、心脏、肝脏、肿瘤和免疫细胞。专有的平台技术可以在单一抗体支架上传递多种治疗性寡核苷酸。AOCs具有类似于抗体的药物性质,并允许将寡核苷酸有效载荷传递到其他运载平台所不提供的非肝组织。AOC也有其独特之处,因为可以处理不可药物的目标。 它们正在推进一系列的治疗计划,重点是罕见的肌肉疾病和其他严重疾病。主要项目是开发治疗杜氏肌营养不良和肌营养不良患者的治疗方法。还与制药合作伙伴合作开展项目。并得到了经验丰富的团队和受人尊敬的生命科学投资者的支持。